THE GAME OF
Glue4Life is a next-generation bioink for 3D bioprinting living tissues and organs.
TOWARDS CLINICAL USE
Glue4Life is biodegradable and manufactured using clinically compatible components, therefore holding great potential for future clinical applications of 3D bioprinted tissues.
The printing process of Glue4Life is simple - no additional crosslinking step is required.
Cell friendly crosslinking method - no cytotoxic components limiting cell survival and functionality during and after printing process. Glue4Life has shown excellent biocompatibility and tissue formation.
Glue4Life offers printable hydrogels with shear-thinning properties resulting in excellent printability and printing quality even with small nozzle diameters.
Glue4Life results in printed structures that maintain their shape during printing process as well as in long-term cultures in vitro.
Glue4Life is a Research to Business project where we focus on the commercialization of our research results.
Our bioink innovation, Glue4Life, is currently developed under Tampere University and project is funded by Business Finland.
Our vision is to shift the paradigm of 3D bioprinting by simplifying the printing process and improving maturation and functionality of the printed tissues.
We envision to advance the development of tissues and organs for future clinical applications by offering bioinks manufactured with clinically compatible components.
UNIQUENESS OF OUR INNOVATION
Glue4Life is a game-changing bioink that does not rely on the traditional ways of crosslinking bioinks.
Our composition is unique for bioinks - no alginate, cellulose and animal-derived polymers needed.
Our multidisciplinary team has over a combined 30 years of expertise in the fields of tissue engineering, polymer chemistry and development of human stem cell therapies. The team has extensive hands-on experience on 3D bioprinting technologies and printing of human stem cells, such as human pluripotent stem cell derived cells. We have clinical mind-set with the focus on finding future solutions to patients in need. Team is complimented by a steering group consisting of business professionals from the 3D printing and health tech sector.
NEWS AND EVENTS
Glue4Life at Finnish Health and Life Science Research Showcase for Investors 30.11.
Our commercial officer Paula Puistola will pitch Glue4Life business case at Finnish Health and Life Science Research Showcase for Investors organized by Business Finland on 30 November. In addition, our project manager Anni Mörö will join her at the Q&A session. Join us online!
Glue4Life at Nordic Innovation Fair 26.9.-17.9.
Meet our project manager Anni Mörö and commercial officer Paula Puistola at Nordic Innovation Fair in Copenhagen! They will have a pitch and a poster presentation about Glue4Life on Tuesday, 26 September 2022. See you there!
Glue4Life in TERMIS-EU Krakow 28.6.-30.6.
Our project manager Anni Mörö will give a podium presentation about next-generation bioinks and the latest research results in 3D bioprinting of cornea on Wednesday, 29 June 2022, at 11:20 at TERMIS-EU in Krakow. Meet us in Krakow!
Glue4Life wins a pitch award in Nordic Innovation Fair
Our project manager Anni Mörö pitched Glue4Life business case in front of an international panels of investors and experts at Nordic Innovation Fair in Copenhagen on 26 September. Glue4Life was one of the eight winners. Congratulations!
Glue4Life in ESB 2022 Bordeaux 4.9.-8.9.
Our commercial officer Paula Puistola will give a podium presentation about her latest research results in multi-material 3D bioprinting of cornea with Glue4Life on Monday, 5 September 2022, at 10:30 at ESB 2022 in Bordeaux. Meet us in Bordeaux!
Glue4Life granted 555 000€ funding by Business Finland
Glue4Life team received major Research to business funding from Business Finland. The grant total is 550 000 €. Research to Business funding is intended for public research organizations for projects in which research groups and researchers aim to develop their research into new business and to commercialize their research results.